MBBCh MMM - Ampio Pharm Chief Officer
| AMPEDelisted Stock | USD 0.24 0.01 4.35% |
Insider
MBBCh MMM is Chief Officer of Ampio Pharm
| Age | 68 |
| Phone | 720 437 6500 |
| Web | https://ampiopharma.com |
Ampio Pharm Management Efficiency
The company has return on total asset (ROA) of (0.6157) % which means that it has lost $0.6157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1396) %, meaning that it created substantial loss on money invested by shareholders. Ampio Pharm's management efficiency ratios could be used to measure how well Ampio Pharm manages its routine affairs as well as how well it operates its assets and liabilities.Ampio Pharm currently holds 274 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Ampio Pharm has a current ratio of 4.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Ampio Pharm until it has trouble settling it off, either with new capital or with free cash flow. So, Ampio Pharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ampio Pharm sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ampio to invest in growth at high rates of return. When we think about Ampio Pharm's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Ileen Winick | Candel Therapeutics | N/A | |
| Filip MD | Monte Rosa Therapeutics | 50 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Ray MD | Akari Therapeutics PLC | 79 | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Seshu Tyagarajan | Candel Therapeutics | 56 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Robert Dudley | Transcode Therapeutics | 73 | |
| Melissa BradfordKlug | Akari Therapeutics PLC | 54 | |
| MD MS | Candel Therapeutics | 53 | |
| FMEDSCI MD | Candel Therapeutics | 62 | |
| Michael Alley | AN2 Therapeutics | N/A | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| Francesca MD | Candel Therapeutics | 46 | |
| Eric Easom | AN2 Therapeutics | 56 | |
| Miles Nunn | Akari Therapeutics PLC | 55 | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
Management Performance
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.62 |
Ampio Pharm Leadership Team
Elected by the shareholders, the Ampio Pharm's board of directors comprises two types of representatives: Ampio Pharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ampio. The board's role is to monitor Ampio Pharm's management team and ensure that shareholders' interests are well served. Ampio Pharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ampio Pharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Corp CFO | ||
| Laura Goldberg, VP Operations | ||
| MBBCh MMM, Chief Officer | ||
| Daniel CPA, Corporate CFO | ||
| Lane Hapke, VP Operations | ||
| April Ramirez, Clinical Manager | ||
| Michael Martino, CEO Director | ||
| David MD, Founder Board |
Ampio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ampio Pharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.62 | ||||
| Current Valuation | (3.33 M) | ||||
| Shares Outstanding | 1.14 M | ||||
| Shares Owned By Insiders | 1.56 % | ||||
| Shares Owned By Institutions | 4.19 % | ||||
| Number Of Shares Shorted | 32.9 K | ||||
| Price To Earning | 28.57 X | ||||
| Price To Book | 0.21 X | ||||
| EBITDA | (8.63 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Ampio Pink Sheet
If you are still planning to invest in Ampio Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ampio Pharm's history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |